{"generic":"Sweet Vernal\/Orchard\/Rye\/Timothy\/Kentucky Blue Grass Mixed Pollen Allergen Extract","drugs":["Oralair","Sweet Vernal\/Orchard\/Rye\/Timothy\/Kentucky Blue Grass Mixed Pollen Allergen Extract"],"mono":{"0":{"id":"jybls0","title":"Generic Names","mono":"Sweet Vernal\/Orchard\/Rye\/Timothy\/Kentucky Blue Grass Mixed Pollen Allergen Extract"},"1":{"id":"jybls1","title":"Dosing and Indications","sub":[{"id":"jybls1b4","title":"Adult Dosing","mono":"<ul><li><b>missed dose:<\/b> no data available regarding safety of restarting treatment after a missed dose<\/li><li><b>Allergic rhinitis due to grass pollens - Grass desensitization therapy:<\/b> 300 index of reactivity SL once daily<\/li><\/ul>"},{"id":"jybls1b5","title":"Pediatric Dosing","mono":"<ul><li><b>missed dose:<\/b> no data available regarding safety of restarting treatment after a missed dose<\/li><li><b>Allergic rhinitis due to grass pollens - Grass desensitization therapy:<\/b> (10 to 17 years) 100 index of reactivity (IR) SL on day 1, then 200 IR SL on day 2, and then 300 IR SL once daily<\/li><\/ul>"},{"id":"jybls1b6","title":"Dose Adjustments","mono":"<b>Geriatric:<\/b> safety and efficacy not evaluated in patients older than 65 years "},{"id":"jybls1b7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><br\/>Allergic rhinitis due to grass pollens - Grass desensitization therapy<br\/>"}]},"2":{"id":"jybls2","title":"Black Box Warning","mono":"<b>Sublingual (Tablet)<\/b><br\/>Use of Sweet Vernal\/Orchard\/Rye\/Timothy\/Kentucky Blue Grass mixed pollen allergen extract may lead to life-threatening allergic reactions including anaphylaxis and severe laryngopharyngeal edema. Do not use in patients with severe asthma that is unstable or uncontrolled. Monitor patients for at least 30 minutes after administration of the initial dose. Prescribe auto-injectable epinephrine and instruct on its use, including when to seek immediate medical care. Sweet Vernal\/Orchard\/Rye\/Timothy\/Kentucky Blue Grass mixed pollen allergen extract may not be appropriate for patients whose medical conditions decrease their ability to survive a serious allergic reaction or for patients who are unresponsive to epinephrine or inhaled bronchodilators, eg, when receiving beta-blocker therapy.<br\/>"},"3":{"id":"jybls3","title":"Contraindications\/Warnings","sub":[{"id":"jybls3b9","title":"Contraindications","mono":"<ul><li>history of eosinophilic esophagitis<\/li><li>history of severe local reaction to sublingual allergen immunotherapy<\/li><li>history of severe systemic allergic reaction<\/li><li>hypersensitivity to any of the inactive ingredients<\/li><li>severe, unstable or uncontrolled asthma <\/li><\/ul>"},{"id":"jybls3b10","title":"Precautions","mono":"<ul><li>Immunologic:<\/li><li>-- severe local reactions, including laryngopharyngeal swelling, which can compromise breathing and be life-threatening may occur; consider discontinuation for escalating or persistent local reactions<\/li><li>-- life threatening systemic allergic reactions, such as anaphylaxis may occur; administer initial dose in a healthcare setting and observe patient for at least 30 minutes after dose and prescribe auto-injectable epinephrine for home use<\/li><li>Gastrointestinal:<\/li><li>-- eosinophilic esophagitis, which may include symptoms such as dysphagia or chest pain, has been reported; discontinue if symptoms are severe or persistent<\/li><li>-- oral inflammation (eg, oral lichen planus, mouth ulcers, or thrush) or wounds (eg, after oral surgery or dental extraction); stop therapy to allow complete healing<\/li><li>Respiratory:<\/li><li>-- acute asthma exacerbation; withhold therapy during exacerbation, reevaluate patient, and consider discontinuation<\/li><li>-- compromised lung function (chronic or acute), unstable angina, recent myocardial infarction, significant arrhythmia, and uncontrolled hypertension; may reduce ability to survive a serious allergic reaction or increase risk of adverse reactions with epinephrine administration<\/li><li>Concomitant Use:<\/li><li>-- concomitant allergen immunotherapy; may increase likelihood of local or systemic adverse reactions to either subQ or SL allergen immunotherapy<\/li><li>-- concomitant beta-adrenergic blockers; may be unresponsive to usual doses of epinephrine used to treat serious systemic reactions, including anaphylaxis<\/li><li>Other:<\/li><li>-- initiation of therapy during grass pollen season; benefit may not outweigh risk<\/li><\/ul>"},{"id":"jybls3b11","title":"Pregnancy Category","mono":"B (FDA)<br\/>"},{"id":"jybls3b12","title":"Breast Feeding","mono":"Micromedex: Infant risk cannot be ruled out.<br\/>"}]},"5":{"id":"jybls5","title":"Adverse Effects","mono":"<b>Common<\/b><ul><li><b>Dermatologic:<\/b>Ear problem, Pruritus (8.4%)<\/li><li><b>Gastrointestinal:<\/b>Edema of oral soft tissues (8.2%), Itching, Oral (25.1%), Itching, Tongue (7.9%)<\/li><li><b>Respiratory:<\/b>Asthma (7.1%), Cough (7.3%), Pain, Oropharyngeal (5.1%), Throat irritation (22%)<\/li><\/ul><b>Serious<\/b><ul><li><b>Gastrointestinal:<\/b>Eosinophilic esophagitis<\/li><li><b>Immunologic:<\/b>Anaphylaxis, Hypersensitivity reaction<\/li><li><b>Respiratory:<\/b>Swelling, Laryngopharyngeal<\/li><\/ul>"},"6":{"id":"jybls6","title":"Drug Name Info","sub":[{"id":"jybls6b17","title":"US Trade Names","mono":"Oralair<br\/>"},{"id":"jybls6b18","title":"Synonyms","mono":"Grass Pollen Extract Combination<br\/>"},{"id":"jybls6b19","title":"Class","mono":"Immunological Agent<br\/>"},{"id":"jybls6b20","title":"Regulatory Status","mono":"RX<br\/>"},{"id":"jybls6b21","title":"Generic Availability","mono":"No<br\/>"}]},"7":{"id":"jybls7","title":"Mechanism Of Action","mono":"The mechanism of action of allergen immunotherapy agents has not been elucidated.<br\/>"},"9":{"id":"jybls9","title":"Administration","mono":"<b>Sublingual<\/b><br\/><ul><li>SL administration only<\/li><li>administer first dose under supervision of a physician with experience in diagnosis and treatment of severe allergic reactions; observe patient for at least 30 minutes<\/li><li>remove from the blister just prior to dosing; place tablet under tongue for at least 1 minute (until complete dissolution) and then swallow<\/li><li>wash hands after handling tablet; avoid food or beverages for 5 minutes after administration<\/li><\/ul>"},"10":{"id":"jybls10","title":"Monitoring","mono":"<ul><li>improvement in symptoms of allergic rhinitis and decreased use of rescue medication is indicative of efficacy<\/li><li>signs or symptoms of severe allergic reaction; observe for at least 30 minutes after initial dose<\/li><li>escalating or persistent local reactions; reevaluate and consider discontinuation of treatment<\/li><li>recurrent asthma exacerbations; reevaluate and consider discontinuation of treatment<\/li><\/ul>"},"11":{"id":"jybls11","title":"How Supplied","mono":"<b>Oralair<\/b><br\/>Sublingual Tablet: (Kentucky Blue Grass Pollen Allergen Extract - Orchard Grass Pollen Allergen Extract - Perennial Rye Grass Pollen Allergen Extract - Sweet Vernal Grass Pollen Allergen Extract - Timothy Grass Pollen Allergen Extract) 9000 BAU<br\/>"},"13":{"id":"jybls13","title":"Clinical Teaching","mono":"<ul><li>Counsel patient about the symptoms of severe allergic reactions and the proper use of emergency self-injection epinephrine.<\/li><li>Instruct patient to immediately report use of emergency self-injection epinephrine.<\/li><li>Advise asthma patient to immediately report breathing difficulty or worsening of asthma symptoms.<\/li><li>Encourage patients to discontinue use and contact a healthcare professional if severe or persistent symptoms of esophagitis develop.<\/li><li>Side effects may include throat irritation, tonsillitis, upper respiratory tract infection, cough, pruritus of the ears, mouth, or tongue, swelling of the mouth or lips, or abdominal pain.<\/li><li>Advise patient to place tablet under tongue and do not swallow until completely dissolved (at least one minute).<\/li><li>Instruct patient to avoid taking drug with food or drink. Do not consume food or drink for at least 5 minutes after dissolution.<\/li><li>Tell patient to wash hands immediately following administration.<\/li><\/ul>"}}}